A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

19 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-02-07

Study Completion Date

2025-02-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a first-in-human Phase 1 clinical trial designed to investigate the safety, tolerability, pharmacokinetics, and biodistribution of \[225Ac\]-FPI-2059 and \[111In\]-FPI-2058 in participants with neurotensin receptor 1 (NTSR1)-expressing solid tumours.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

NCT06147037

Advanced Solid Tumor Metastatic Colorectal Carcinoma Head and Neck Squamous Cell Carcinoma +4 more

RECRUITING PHASE1

First-in-Human Study of MS201408-0005A as Single Agent and in Combinations

NCT03306420

Metastatic or Locally Advanced Unresectable Solid Tumors

TERMINATED PHASE1

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

NCT05538130

Melanoma Glioma Thyroid Cancer +10 more

RECRUITING PHASE1

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

NCT07006727

Small Cell Lung Carcinoma Large Cell Neuroendocrine Carcinoma of the Lung Neuroendocrine Prostate Cancer +1 more

RECRUITING PHASE1

A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors

NCT00923728

Refractory Solid Tumors

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a first-in-human, Phase 1, non-randomized, multi-centre, open-label clinical trial designed to investigate the safety, tolerability, dosimetry, biodistribution, and pharmacokinetics (PK) of \[225Ac\]-FPI-2059 and \[111In\]-FPI-2058, as well as the pharmacodynamics and preliminary anti-tumour activity of \[225Ac\]-FPI-2059 in participants with neurotensin receptor 1 (NTSR1)-expressing advanced, metastatic and/or recurrent solid tumours.

The study will employ a 3+3 dose escalation design to identify the recommended phase 2 dose (RP2D) and regimen of \[225Ac\]-FPI-2059 administered intravenously every 56 days.

After the RP2D for \[225Ac\]-FPI-2059 is determined, enrolment will continue into an expansion cohort, to confirm the safety and tolerability of the RP2D, as well as to identify any preliminary evidence of efficacy in selected NTSR1-expressing tumour types.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatic Ductal Adenocarcinoma (PDAC) Squamous Cell Carcinoma of Head and Neck Colorectal Cancer Gastric Cancer Ewing Sarcoma NTSR1 Expressing Solid Tumours Neuroendocrine Differentiated (NED) Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Phase 1 Dose Escalation

Group Type EXPERIMENTAL

[225]-FPI-2059

Intervention Type DRUG

\[225Ac\]-FPI-2059 is a targeted alpha therapeutic that consists of an NTSR1-targeting small molecule that is linked to Ac-225, an alpha particle emitting radionuclide. Participants will be dosed through IV administration every 56 days up to four cycles. The dose depends on cohort assignment.

In the Dose Expansion arm, \[225Ac\]-FPI-2059 will be administered at the RP2D as determined in Phase 1 Dose Escalation.

[111In]-FPI-2058

Intervention Type DRUG

\[111In\]-FPI-2058 is an imaging agent that consists of an NTSR1-targeting small molecule linked to In-111.Participants will receive \[111In\]-FPI-2058 by IV Injection for imaging once during screening period. The dose is consistent across cohorts.

Phase 1 Dose Expansion

Group Type EXPERIMENTAL

[225]-FPI-2059

Intervention Type DRUG

\[225Ac\]-FPI-2059 is a targeted alpha therapeutic that consists of an NTSR1-targeting small molecule that is linked to Ac-225, an alpha particle emitting radionuclide. Participants will be dosed through IV administration every 56 days up to four cycles. The dose depends on cohort assignment.

In the Dose Expansion arm, \[225Ac\]-FPI-2059 will be administered at the RP2D as determined in Phase 1 Dose Escalation.

[111In]-FPI-2058

Intervention Type DRUG

\[111In\]-FPI-2058 is an imaging agent that consists of an NTSR1-targeting small molecule linked to In-111.Participants will receive \[111In\]-FPI-2058 by IV Injection for imaging once during screening period. The dose is consistent across cohorts.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

[225]-FPI-2059

\[225Ac\]-FPI-2059 is a targeted alpha therapeutic that consists of an NTSR1-targeting small molecule that is linked to Ac-225, an alpha particle emitting radionuclide. Participants will be dosed through IV administration every 56 days up to four cycles. The dose depends on cohort assignment.

In the Dose Expansion arm, \[225Ac\]-FPI-2059 will be administered at the RP2D as determined in Phase 1 Dose Escalation.

Intervention Type DRUG

[111In]-FPI-2058

\[111In\]-FPI-2058 is an imaging agent that consists of an NTSR1-targeting small molecule linked to In-111.Participants will receive \[111In\]-FPI-2058 by IV Injection for imaging once during screening period. The dose is consistent across cohorts.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed ICF prior to initiation of any study-specific procedures
* Histologically and/or cytologically confirmed solid tumor that is metastatic or locally advanced, inoperable, or recurrent. Solid tumors indications may include PDAC, CRC, NED prostate cancer, gastric cancer, SCCHN, and Ewing sarcoma.
* Disease that has progressed despite prior treatment, and for which additional effective standard therapy is not available or is contraindicated, not tolerable, or the patient refuses standard therapy
* Measurable disease per RECIST v.1.1
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Sufficient target expression in at least one measurable lesion as determined by imaging following injection of \[111In\]-FPI-2058
* Adequate organ function
* Tumor tissue (either archival within the last 24 months or fresh biopsy)

Exclusion Criteria

* Previous treatment with any radiopharmaceutical
* Contraindications to or inability to perform the imaging procedures required in this study
* Anti-cancer therapy, such as chemotherapy, immunotherapy, hormonal therapy, targeted therapy, or investigational agents within certain amount of time prior to administration of the first dose of \[111In\]-FPI-2058
* Radiation therapy (RT) within 28 days prior to the first dose of \[111In\]-FPI-2058
* Patients with known CNS metastatic disease
* Concurrent severe and/or uncontrolled illness that would limit compliance with study requirements
* Known or suspected allergies or contraindication to the investigational treatment
* Received any type of vaccine within 30 days prior to the first dose of \[111In\]-FPI-2058

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No